Scholarlink

<p>Guideline-directed medical therapy is the backbone of heart failure treatment. However, patients continue to experience heart failure symptoms, impaired quality of life, and reduced functional status despite guideline-directed medical and device treatment. There is a void in treatment alternatives between guideline-directed therapy and the advanced heart failure surgical options of heart transplant (HT) and left ventricular assist device (LVAD). Cardiac contractility modulation and baroreceptor activation therapies are shown to improve heart failure symptoms, quality of life, and exertional capacity in select patients and complement our current treatment paradigm. The purpose of this paper is to review these novel Food and Drug Administration (FDA)-approved heart failure therapies and facilitate the identification of appropriate candidates.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Beyond GDMT: bridging the therapeutic gap in heart failure

  • 期刊论文

  • 发表日期：

    2025年4月30日

查看全文
  • Laurie A. Letarte,
  • Vikram Raje,
  • Jason P. Feliberti,
  • Steve M. Antoine,
  • Amarinder S. Bindra,
  • Dmitry M. Yaranov,
  • Amin Yehya,
  • Rachel A. Garcia,
  • Pujan Patel,
  • Marat Fudim,
  • Brian Howard,
  • Vishal N. Rao,
  • Albert Hicks III,
  • Kiran Mahmood,
  • Richa Gupta,
  • Allman Rollins,
  • Amit Alam,
  • Patrick McCann,
  • Nirav Y. Raval

摘要

Guideline-directed medical therapy is the backbone of heart failure treatment. However, patients continue to experience heart failure symptoms, impaired quality of life, and reduced functional status despite guideline-directed medical and device treatment. There is a void in treatment alternatives between guideline-directed therapy and the advanced heart failure surgical options of heart transplant (HT) and left ventricular assist device (LVAD). Cardiac contractility modulation and baroreceptor activation therapies are shown to improve heart failure symptoms, quality of life, and exertional capacity in select patients and complement our current treatment paradigm. The purpose of this paper is to review these novel Food and Drug Administration (FDA)-approved heart failure therapies and facilitate the identification of appropriate candidates.